视网膜静脉阻塞伴黄斑水肿患者行玻璃体腔注射康柏西普治疗的效果分析

【摘要】 目的 探讨对视网膜静脉阻塞合并黄斑水肿患者选择康柏西普进行玻璃体腔注射治疗后获得的临床效果。方法 选择2015年1月至2017年10月66例视网膜静脉阻塞合并黄斑水肿患者,采用数字奇偶法分组。对照组(33例)选择激光光凝疗法;观察组(33例)选择激光光凝+玻璃体腔注射康柏西普疗法。比较两组患者病症治疗总有效率、黄斑中心凹视网膜厚度以及并发症发生率。结果 与对照组患者治疗总有效率(66.67%)比较,观察组治疗总有效率(96.97%)明显提升(P<0.05);与对照组患者比较,观察组黄斑中心凹视网膜厚度显著减小(P<0.05);与对照组患者并发症发生率(30.30%)比较,观察组并发症发生率(9.09%)显著减少(P<0.05)。结论 对于视网膜静脉阻塞合并黄斑水肿患者临床选择康柏西普药物进行玻璃体腔注射治疗,在提高疗效、减少黄斑中心凹视网膜厚度以及减少并发症方面优势明显,从而促进视网膜静脉阻塞合并黄斑水肿患者病情好转。更多还原

【Abstract】 Objective To explore the clinical effect of patients with retinal vein occlusion combined with macular edema in the selection of vitreous chamber injection for injection. Methods 66 cases of retinal vein occlusion and macular edema were selected in our hospital from January 2015 to October 2017. Using the digital parity method, they were divided into two groups. Control group( 33 cases) was given laser photocoagulation therapy. Observation group( 33 cases) was given selective laser photocoagulation+glass body cavity injection of conbercept. Finally, the total effective efficiency, the retinal thickness of macular center and the incidence of complications in the two groups were compared. Results The total effective rate(66.67%) of control group compared with that in observation group( 96.97%), showed a significant improvement( P<0.05). Comparison of retinal thickness in macular center with macular edema in patients with retinal vein occlusion in the control group showed significant reduction( P<0.05). The complication rate( 30.30%) of patients with retinal vein occlusion and macular edema in the control group were compared, and the observation group(9.09%) showed a significant decrease( P<0.05). Conclusion For patients with retinal vein occlusion with macular edema, conbercept has obvious advantages in improving curative effect, reducing macular fovea retinal thickness and reducing complications, thus promoting the improvement of patients with retinal vein occlusion combined with macular edema.更多还原